Haw Par Corporation Limited (HAWPF)
USD 10.0
(19.47%)
USD 10.0
(19.47%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -546.16 Million SGD | -79.03% |
| 2022 | -305.06 Million SGD | 48.77% |
| 2021 | -595.46 Million SGD | -7.58% |
| 2020 | -553.52 Million SGD | -21.16% |
| 2019 | -456.83 Million SGD | 7.97% |
| 2018 | -496.37 Million SGD | -39.46% |
| 2017 | -355.93 Million SGD | -33.2% |
| 2016 | -267.21 Million SGD | 1.83% |
| 2015 | -272.18 Million SGD | -61.69% |
| 2014 | -168.33 Million SGD | 9.73% |
| 2013 | -186.48 Million SGD | -3808.15% |
| 2012 | 5.02 Million SGD | 239.08% |
| 2011 | -3.61 Million SGD | 96.75% |
| 2010 | -111.35 Million SGD | -28.07% |
| 2009 | -86.94 Million SGD | -265.56% |
| 2008 | -23.78 Million SGD | -29.85% |
| 2007 | -18.31 Million SGD | -15.48% |
| 2006 | -15.86 Million SGD | -9.39% |
| 2005 | -14.49 Million SGD | -85.36% |
| 2004 | -7.82 Million SGD | -109.42% |
| 2003 | 83.07 Million SGD | -35.56% |
| 2002 | 128.9 Million SGD | -12.57% |
| 2001 | 147.43 Million SGD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -446.58 Million SGD | 0.0% |
| 2024 Q1 | -446.58 Million SGD | 18.23% |
| 2023 FY | -546.16 Million SGD | -79.03% |
| 2023 Q2 | -248.29 Million SGD | 0.0% |
| 2023 Q3 | -546.16 Million SGD | -119.97% |
| 2023 Q1 | -248.29 Million SGD | 18.61% |
| 2023 Q4 | -546.16 Million SGD | 0.0% |
| 2022 Q1 | -587.14 Million SGD | 1.4% |
| 2022 Q4 | -305.06 Million SGD | 0.23% |
| 2022 FY | -305.06 Million SGD | 48.77% |
| 2022 Q3 | -305.76 Million SGD | 47.92% |
| 2022 Q2 | -587.14 Million SGD | 0.0% |
| 2021 Q3 | -596.22 Million SGD | -3.79% |
| 2021 FY | -595.46 Million SGD | -7.58% |
| 2021 Q2 | -574.45 Million SGD | 0.0% |
| 2021 Q4 | -595.46 Million SGD | 0.13% |
| 2021 Q1 | -574.45 Million SGD | -3.78% |
| 2020 Q4 | -553.52 Million SGD | 0.16% |
| 2020 FY | -553.52 Million SGD | -21.16% |
| 2020 Q2 | -580.09 Million SGD | 0.0% |
| 2020 Q3 | -554.41 Million SGD | 4.43% |
| 2020 Q1 | -580.09 Million SGD | -26.98% |
| 2019 Q4 | -456.83 Million SGD | -9.69% |
| 2019 Q2 | -383.52 Million SGD | 24.29% |
| 2019 Q3 | -416.48 Million SGD | -8.59% |
| 2019 Q1 | -506.58 Million SGD | -2.06% |
| 2019 FY | -456.83 Million SGD | 7.97% |
| 2018 Q2 | -446.68 Million SGD | -3.15% |
| 2018 Q3 | -471.07 Million SGD | -5.46% |
| 2018 Q4 | -496.37 Million SGD | -5.37% |
| 2018 Q1 | -433.02 Million SGD | -21.66% |
| 2018 FY | -496.37 Million SGD | -39.46% |
| 2017 FY | -355.93 Million SGD | -33.2% |
| 2017 Q4 | -355.93 Million SGD | -16.54% |
| 2017 Q3 | -305.41 Million SGD | -8.02% |
| 2017 Q2 | -282.74 Million SGD | -2.58% |
| 2017 Q1 | -275.61 Million SGD | -3.15% |
| 2016 Q1 | -292.27 Million SGD | -7.38% |
| 2016 Q2 | -270.61 Million SGD | 7.41% |
| 2016 Q3 | -243.36 Million SGD | 10.07% |
| 2016 Q4 | -267.21 Million SGD | -9.8% |
| 2016 FY | -267.21 Million SGD | 1.83% |
| 2015 Q2 | -215.21 Million SGD | -20.25% |
| 2015 FY | -272.18 Million SGD | -61.69% |
| 2015 Q4 | -272.18 Million SGD | -6.59% |
| 2015 Q3 | -255.35 Million SGD | -18.65% |
| 2015 Q1 | -178.97 Million SGD | -6.32% |
| 2014 FY | -168.33 Million SGD | 9.73% |
| 2014 Q1 | -165.44 Million SGD | 11.28% |
| 2014 Q4 | -168.33 Million SGD | 0.96% |
| 2014 Q3 | -169.97 Million SGD | -16.09% |
| 2014 Q2 | -146.4 Million SGD | 11.51% |
| 2013 Q2 | 8.36 Million SGD | -22.79% |
| 2013 Q1 | 10.82 Million SGD | 115.33% |
| 2013 Q4 | -186.48 Million SGD | -3114.11% |
| 2013 Q3 | 6.18 Million SGD | -26.0% |
| 2013 FY | -186.48 Million SGD | -3808.15% |
| 2012 FY | 5.02 Million SGD | 239.08% |
| 2012 Q1 | -3.53 Million SGD | 2.35% |
| 2012 Q2 | 915 Thousand SGD | 125.91% |
| 2012 Q3 | 5.66 Million SGD | 518.91% |
| 2012 Q4 | 5.02 Million SGD | -11.2% |
| 2011 Q3 | -6.99 Million SGD | 58.49% |
| 2011 Q1 | -114.38 Million SGD | -2.72% |
| 2011 Q2 | -16.83 Million SGD | 85.28% |
| 2011 Q4 | -3.61 Million SGD | 48.27% |
| 2011 FY | -3.61 Million SGD | 96.75% |
| 2010 Q1 | -92.31 Million SGD | -6.17% |
| 2010 Q3 | -95.38 Million SGD | 6.48% |
| 2010 Q2 | -101.99 Million SGD | -10.49% |
| 2010 FY | -111.35 Million SGD | -28.07% |
| 2010 Q4 | -111.35 Million SGD | -16.74% |
| 2009 FY | -86.94 Million SGD | -265.56% |
| 2009 Q4 | -86.94 Million SGD | 0.0% |
| 2008 FY | -23.78 Million SGD | -29.85% |
| 2007 FY | -18.31 Million SGD | -15.48% |
| 2006 FY | -15.86 Million SGD | -9.39% |
| 2005 FY | -14.49 Million SGD | -85.36% |
| 2004 FY | -7.82 Million SGD | -109.42% |
| 2003 FY | 83.07 Million SGD | -35.56% |
| 2002 FY | 128.9 Million SGD | -12.57% |
| 2002 Q4 | 129.46 Million SGD | 0.0% |
| 2002 Q2 | 77.53 Million SGD | 0.0% |
| 2001 FY | 147.43 Million SGD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 102.401% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 101.821% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 65.737% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 3544.985% |
| Novartis AG | 12.95 Billion USD | 104.216% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | -221.84% |